Physician profile
Deborah E Connatser
NPI 1265718944
$11,999.06
in general payments reported to CMS, 2019-2025
28 companies · $3,379 in 2025
The $3,379 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,435 · 2022: $1,709 · 2023: $2,521 · 2024: $2,956 · 2025: $3,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,534 · Consulting Fee: $1,945 · Education: $361 · Travel and Lodging: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,533.53 |
| Consulting Fee | $1,945.00 |
| Education | $360.90 |
| Travel and Lodging | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,257.10 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $2,057.66 | 2021-2025 | |
| Abbvie INC. | $1,300.93 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $859.21 | 2023 | Spevigo |
| Sun Pharmaceutical Industries INC. | $837.18 | 2021-2025 | Ilumya |
| Ucb, INC. | $679.29 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $599.29 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $556.62 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $548.69 | 2022-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $397.71 | 2021-2025 | |
| Pfizer INC. | $347.31 | 2021-2024 | |
| Genzyme Corporation | $274.09 | 2021-2025 | |
| Dermavant Sciences, INC. | $257.99 | 2023-2024 | Vtama |
| Almirall LLC | $245.75 | 2021-2025 | Seysara |
| Janssen Scientific Affairs, LLC | $106.89 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $105.07 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $84.99 | 2021-2023 | Libtayo |
| Galderma Laboratories, L.P. | $79.83 | 2021-2025 | Nemluvio |
| Leo Pharma INC. | $71.59 | 2021-2025 | Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $66.70 | 2021-2025 | Jublia, Cabtreo |
| Amgen INC. | $51.40 | 2023-2024 | Otezla |
| Epi Health, LLC | $50.57 | 2021-2022 | |
| Incyte Corporation | $41.72 | 2023-2024 | Opzelura |
| Organon LLC | $28.54 | 2025 | |
| Mallinckrodt Hospital Products INC. | $26.52 | 2025 | Acthar |
| Cipher Pharmaceuticals US LLC | $23.80 | 2025 | Natroba, Spinosad |
| Merz North America, INC. | $23.13 | 2021 | |
| Genentech USA, INC. | $19.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Connatser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.